Logotipo ImpactU
Autor

Preventing The Next Pandemic: Is Live Vaccine Efficacious Against Monkeypox, or There is a Need for Killed Virus and mRNA Vaccines?

Acceso Abierto

Abstract:

(1) Background: The monkeypox virus (MPV) is a double-stranded DNA virus belonging to the Poxviridae family, Chordopoxvirinae subfamily, and Or-thopoxvirus genu. It was called monkeypox because it was first discovered in monkeys, in a Danish laboratory, in 1958. However, the actual reservoir for MPV is still unknown. (2) Methods & Results: We have reviewed the existing literature on the options for Monkeypox virus. There are three available vaccines for orthopoxviruses: ACAM2000, JYNNEOS, and LC16, with the first being a replicating vaccine and the latter being non or minimally replicating. (3) Conclusions: Smallpox vaccinations previously provided coincidental im-munity to MPV. ACAM2000(a live‐attenuated replicating vaccine) and JYNNEOS (a live‐attenuated, non-replicating vaccine) are two US FDA‐approved vaccines that can prevent monkeypox. However, ACAM2000 may cause serious side effects, including cardiac problems, whereas JYNNEOS is associated with fewer com-plications. The recent outbreaks across the globe have once again highlighted the need for constant monitoring and the development of novel prophylactic and therapeutic modalities. Based on available data, there is still a need to develop an effective and safe new generation of vaccines specific for monkeypox that are killed or mRNA before monkeypox is declared a pandemic.

Tópico:

Poxvirus research and outbreaks

Citaciones:

Citations: 10
10

Citaciones por año:

Altmétricas:

Paperbuzz Score: 0
0

Información de la Fuente:

FuenteNo disponible
Cuartil año de publicaciónNo disponible
VolumenNo disponible
IssueNo disponible
PáginasNo disponible
pISSNNo disponible
ISSNNo disponible
Perfil OpenAlexNo disponible

Enlaces e Identificadores:

Artículo de revista